IGF-1

IGF-1 (insulin-like growth factor 1; somatomedin C) is an endogenous 70-amino-acid polypeptide produced primarily in the liver in response to growth hormone signaling, functioning as the principal mediator of GH anabolic effects through its receptor (IGF-1R) expressed in virtually all tissues, with roles in muscle protein synthesis, bone growth, and cellular proliferation. IGF-1 activates IGF-1R tyrosine kinase to stimulate PI3K/Akt and MAPK/ERK signaling cascades, promoting protein synthesis, cell survival, and glucose uptake in muscle and bone; endogenous IGF-1 levels peak during puberty and decline with age, and GH-stimulating interventions exert many of their effects by elevating circulating IGF-1.

muscle growth, Recovery, fat metabolism, tissue repair, GH axis.

Research on IGF-1 primarily documents effects related to muscle growth and Recovery and fat metabolism and tissue repair and GH axis. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For IGF-1, its FDA status is FDA-approved, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

17 providers in the directory currently offer IGF-1.

Across 8 research vendors tracked on PeptideBase, IGF-1 has a median price of about $54.33 per mg, typically ranging $29.30–$73.44 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

# Summary Research found that in acromegaly patients, elevated IGF-1 levels directly drive subclinical cardiac dysfunction, with this effect significantly amplified by concurrent metabolic dysregulation (elevated BMI and triglyceride-glucose levels). This study demonstrated that patients achieving biochemical remission showed improved cardiac structure and function, supporting the use of speckle-tracking echocardiography for early detection and risk stratification of cardiac involvement in this condition.